PAPER Orme RP, Bhangal MS, Fricker RA
SEARCH RESULTS
331254 RESULTS
PAPER Nguyen HP, Hübener J, Weber JJ, Grueninger S, Riess O, Weiss A
Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
PLoS One. 2013;8(4):e62043. PubMed: 23626768PAPER Khoutorsky A, Yanagiya A, Gkogkas CG, Fabian MR, Prager-Khoutorsky M, Cao R, Gamache K, Bouthiette F, Parsyan A, Sorge RE, Mogil JS, Nader K, Lacaille JC, Sonenberg N
Control of synaptic plasticity and memory via suppression of poly(A)-binding protein.
Neuron. 2013 Apr 24;78(2):298-311. PubMed: 23622065PAPER Trempe JF, Fon EA
Structure and Function of Parkin, PINK1, and DJ-1, the Three Musketeers of Neuroprotection.
Front Neurol. 2013;4:38. PubMed: 23626584PAPER Cousins SL, Innocent N, Stephenson FA
Neto1 associates with the NMDA receptor/amyloid precursor protein complex.
J Neurochem. 2013 Apr 29; PubMed: 23621516PAPER Blum D, Buée L
Alzheimer's disease risk, obesity and tau: is insulin resistance guilty?
Expert Rev Neurother. 2013 May;13(5):461-3. PubMed: 23621301PAPER Nelson L, Tabet N, Richardson C, Gard P
Antihypertensives, angiotensin, glucose and Alzheimer's disease.
Expert Rev Neurother. 2013 May;13(5):477-82. PubMed: 23621305PAPER Radanovic M, Pereira FR, Stella F, Aprahamian I, Ferreira LK, Forlenza OV, Busatto GF
White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies.
Expert Rev Neurother. 2013 May;13(5):483-93. PubMed: 23621306PAPER Medina M, Avila J
Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.
Expert Rev Neurother. 2013 May;13(5):495-503. PubMed: 23621307PAPER Hafner A, Glavan G, Obermajer N, Zivin M, Schliebs R, Kos J
Neuroprotective role of γ-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X.
Aging Cell. 2013 Aug;12(4):604-14. PubMed: 23621429PAPER Rocha S
Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer's Disease.
Curr Pharm Des. 2013 Apr 23; PubMed: 23621533PAPER Singleton AB
Finding risk in all the right places.
Neuron. 2013 Apr 24;78(2):207-8. PubMed: 23622057PAPER Qin J, Lan W, Liu Z, Huang J, Tang H, Wang H
Synthesis and biological evaluation of 1, 3-dihydroxyxanthone mannich base derivatives as anticholinesterase agents.
Chem Cent J. 2013;7(1):78. PubMed: 23622085PAPER Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, Zhang C, Xie T, Tran L, Dobrin R, Fluder E, Clurman B, Melquist S, Narayanan M, Suver C, Shah H, Mahajan M, Gillis T, Mysore J, MacDonald ME, Lamb JR, Bennett DA, Molony C, Stone DJ, Gudnason V, Myers AJ, Schadt EE, Neumann H, Zhu J, Emilsson V
Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease.
Cell. 2013 Apr 25;153(3):707-20. PubMed: 23622250PAPER Ozdemir MB, Erdogan C, Iwasaki K, Watanabe T, Ishikane S, Fujiwara M
Injection of specific amyloid-beta oligomers (beta1-40:beta1-42=10:1) into rat medial septum impairs memory retention without inducing hippocampal apoptosis.
Neurol Res. 2013 Apr 23; PubMed: 23622689Current Filters
No filters selected